Septerna, Inc.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Septerna, Inc. | ||
| Date: March 27, 2025 | By: | /s/ Jeffrey Finer, M.D., Ph.D. |
|---|---|---|
| Jeffrey Finer, M.D., Ph.D. | ||
| President and Chief Executive Officer | ||
POWER OF ATTORNEY AND SIGNATURES
KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Jeffrey Finer and Gil M. Labrucherie, as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed by the following person in the capacities and on the date indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Jeffrey Finer, M.D., Ph.D. | President, Chief Executive Officer and Director | March 27, 2025 |
| Jeffrey Finer, M.D., Ph.D. | (principal executive officer) | |
| /s/ Gil M. Labrucherie, CFA, J.D. | Chief Financial Officer | March 27, 2025 |
| Gil M. Labrucherie, CFA, J.D. | (principal financial officer and principal accounting officer) | |
| /s/ Jeffrey Tong, Ph.D. | Chairman and Director | March 27, 2025 |
| Jeffrey Tong, Ph.D. | ||
| /s/ Abraham Bassan, M.S. | Director | March 27, 2025 |
| Abraham Bassan, M.S. | ||
| /s/ Bernard Coulie, M.D., Ph.D., M.B.A. | Director | March 27, 2025 |
| Bernard Coulie, M.D., Ph.D., M.B.A. | ||
| /s/ Alan Ezekowitz, M.D., D.Phil. | Director | March 27, 2025 |
| Alan Ezekowitz, M.D., D.Phil. | ||
| /s/ Shalini Sharp, M.B.A. | Director | March 27, 2025 |
| Shalini Sharp, M.B.A. | ||
| /s/ Jake Simson, Ph.D. | Director | March 27, 2025 |
| Jake Simson, Ph.D. | ||
Index to Financial Statements
Financial Statements as of and for the Years Ended December 2024 and 2023
| Report of Independent Registered Public Accounting Firm (PCAOB ID:42) | F-2 |
|---|---|
| Financial Statements | |
| Balance Sheets | F-3 |
| Statements of Operations and Comprehensive (Loss) Income | F-4 |
| Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) | F-5 |
| Statements of Cash Flows | F-6 |
| Notes to Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.